← Back to Screener
Chemomab Therapeutics Ltd. American Depositary Share (CMMB)
Price$1.67
Favorite Metrics
Price vs S&P 500 (26W)-55.99%
Price vs S&P 500 (4W)-21.82%
Market Capitalization$12.08M
All Metrics
Book Value / Share (Quarterly)$0.02
P/TBV (Annual)0.18x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.02
Price vs S&P 500 (YTD)-0.82%
EPS (TTM)$-0.05
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-0.05
EPS (Annual)$-0.02
ROI (Annual)-72.93%
Cash / Share (Quarterly)$0.02
ROA (Last FY)-65.12%
EBITD / Share (TTM)$-0.03
ROE (5Y Avg)-83.02%
Cash Flow / Share (Annual)$-0.02
P/B Ratio0.98x
P/B Ratio (Quarterly)0.82x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-112.45x
ROA (TTM)-71.78%
EPS Incl Extra (Annual)$-0.02
Current Ratio (Annual)9.08x
Quick Ratio (Quarterly)7.01x
3-Month Avg Trading Volume0.08M
52-Week Price Return-64.41%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$28.37
52-Week High$5.88
EPS Excl Extra (Annual)$-0.02
CapEx CAGR (5Y)-40.43%
26-Week Price Return-52.00%
Quick Ratio (Annual)7.01x
13-Week Price Return-8.20%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.08x
Enterprise Value$4.519
Book Value / Share Growth (5Y)-74.18%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.02
3-Month Return Std Dev88.79%
Net Income / Employee (TTM)$-1
ROE (Last FY)-72.93%
Net Interest Coverage (Annual)-24.86x
EPS Basic Excl Extra (Annual)$-0.02
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.05
ROI (TTM)-82.42%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$49.83
Price vs S&P 500 (52W)-94.24%
Year-to-Date Return1.82%
5-Day Price Return0.60%
EPS Normalized (Annual)$-0.02
ROA (5Y Avg)-68.05%
Month-to-Date Return7.01%
Cash Flow / Share (TTM)$-47.12
EBITD / Share (Annual)$-0.02
ROI (5Y Avg)-83.02%
EPS Basic Excl Extra (TTM)$-0.05
P/TBV (Quarterly)0.30x
P/B Ratio (Annual)0.82x
Book Value / Share (Annual)$0.02
Price vs S&P 500 (13W)-8.88%
Beta0.61x
Revenue / Share (TTM)$0.00
ROE (TTM)-82.42%
52-Week Low$1.35
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CMMBChemomab Therapeutics Ltd. American Depositary Share | — | — | — | — | $1.67 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Chemomab Therapeutics is a clinical-stage biotech company developing CM-101, a monoclonal antibody targeting CCL24 for fibrosis-related diseases with significant unmet medical needs. The company's lead candidate employs a novel mechanism to address liver, skin, and lung fibrosis, with three Phase 2 trials currently underway for rare fibrotic conditions.